Business · 08/05/2025Updated: 10/17/2026 · 1 min read
FDA Announces Public Advisory Committee Meeting for Oncologic Drugs
Summary
The FDA is hosting a public meeting of the Oncologic Drugs Advisory Committee to provide advice on several new and supplemental biologics license applications, including COLUMVI, DARZALEX FASPRO, (mitomycin) Intravesical Solution, and TALZENNA, and is seeking public comments on the applications.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →